DarioHealth Begins Selling iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter in the U.K.

CAESAREA, Israel, Jan. 8, 2018

Apple iOS has just over 50% market share in the U.K. With additional potential users, DarioHealth believes that it will be able to quickly increase U.K.-driven revenues and achieve greater market penetration.

This news comes shortly after the company's recent announcement of receiving the Therapeutic Goods Administration (TGA) Mark in the Australian market for the same Lightning®-enabled device.  Sales of the device are expected to begin in Australia mid-January. DarioHealth expects to hear from the U.S. Food and Drug Administration (F.D.A.) about necessary clearance over the next few months.

"As the digital world continuously evolves, we are committed to offering people with diabetes the most up-to-date technology to manage the disease," said Erez Raphael, Chairman and CEO of DarioHealth. "We are excited to begin sales of our Lightning®-enabled device in the U.K. and we look forward to doing the same in Australia and the U.S."

About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app give users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes that it believes it will be able to quickly increase U.K.-driven revenues and achieve greater market penetration, begin sales in Australia in mid-January and in the United Stated in the future, and that it expects to hear from the F.D.A. about necessary clearance over the next few months, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director, shmuel@mydario.com, Tel: +1-914-775-5548

DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, terese@rosica.com, Tel: +1-201-843-5600

DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com, Tel: +1-443-213-0500